Loading…

Bacterial resistance and failure of clinical cure could be produced by oxidative stress in patients with diabetes or cardiovascular diseases during fluoroquinolone therapy

Abstract Fluoroquinolone agents are used widely for the treatment of infectious diseases which are a common cause of deaths around the world. The level of oxidative stress in patients taking fluoroquinolone antibiotics has not been considered a factor to reduce the clinical efficacy of this kind of...

Full description

Saved in:
Bibliographic Details
Published in:Medical hypotheses 2017-06, Vol.103, p.32-34
Main Authors: Aragon-Martinez, Othoniel H, Martinez-Morales, Flavio, Isiordia-Espinoza, Mario A, Luque Contreras, Diana, Zapata Morales, Juan R, Gonzalez-Rivera, Maria L
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c411t-c6a2cbd9293ad6ad8a826ae4e12a51b97689023afd8b3402e2ff3c770d735ec83
cites cdi_FETCH-LOGICAL-c411t-c6a2cbd9293ad6ad8a826ae4e12a51b97689023afd8b3402e2ff3c770d735ec83
container_end_page 34
container_issue
container_start_page 32
container_title Medical hypotheses
container_volume 103
creator Aragon-Martinez, Othoniel H
Martinez-Morales, Flavio
Isiordia-Espinoza, Mario A
Luque Contreras, Diana
Zapata Morales, Juan R
Gonzalez-Rivera, Maria L
description Abstract Fluoroquinolone agents are used widely for the treatment of infectious diseases which are a common cause of deaths around the world. The level of oxidative stress in patients taking fluoroquinolone antibiotics has not been considered a factor to reduce the clinical efficacy of this kind of drugs. Patients with diabetes and/or cardiovascular diseases present abnormal levels of oxidative stress in the blood stream. In this regards, our hypothesis supposes that patients with diabetes and/or cardiovascular disease suffering a bacterial disease could experience a therapeutic failure and bacterial resistance when treated with fluoroquinolones. The crucial mechanism could be an inefficient blood distribution of the drug via red blood cell dysfunction induced by oxidative stress that might reduce the pharmacokinetic-pharmacodinamic ratios. In this way, we review the scientific information to support our hypothesis alongside possible implications. Additionally, this work exhibits the urgent need of studies considering these conditions for quinolone agents.
doi_str_mv 10.1016/j.mehy.2017.04.004
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1905736504</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S030698771631012X</els_id><sourcerecordid>1905736504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-c6a2cbd9293ad6ad8a826ae4e12a51b97689023afd8b3402e2ff3c770d735ec83</originalsourceid><addsrcrecordid>eNp9UsuO1DAQjBCIHRZ-gAPykcuEtp3EiYSQYMVLWokDIHGzOnaH8ZCJg-0MzDfxkzjMLgcOnLrVXVWyq7ooHnMoOfDm2b480O5UCuCqhKoEqO4UG15LsRVKqbvFBiQ0265V6qJ4EOMeALpKtveLC9HWirdQbYpfr9AkCg5HFii6mHAyxHCybEA3LoGYH5gZ3eRMhph1YPwyWtYTm4O3i6Hcn5j_6SwmdyQWUxaKzE1szgOaUmQ_XNox67CnRJH5wAwG6_wRo1lGDHkVCWNe2SW46SsbxsUH_31xkx_9RCztKOB8eljcG3CM9OimXhaf37z-dPVue_3h7furl9dbU3GetqZBYXrbiU6ibdC22IoGqSIusOZ9p5q2AyFxsG0vKxAkhkEapcAqWZNp5WXx9Kw7r4-gmPTBRUPjiBP5JWreQa1kU0OVoeIMNcHHGGjQc3AHDCfNQa8h6b1eQ9JrSBoqDX9IT270l_5A9i_lNpUMeH4GUP7l0VHQ0WQns9UukEnaevd__Rf_0G8D_EYninu_hCn7p7mOQoP-uJ7JeiW8kVlSfJG_AfTSvW4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1905736504</pqid></control><display><type>article</type><title>Bacterial resistance and failure of clinical cure could be produced by oxidative stress in patients with diabetes or cardiovascular diseases during fluoroquinolone therapy</title><source>ScienceDirect Freedom Collection</source><creator>Aragon-Martinez, Othoniel H ; Martinez-Morales, Flavio ; Isiordia-Espinoza, Mario A ; Luque Contreras, Diana ; Zapata Morales, Juan R ; Gonzalez-Rivera, Maria L</creator><creatorcontrib>Aragon-Martinez, Othoniel H ; Martinez-Morales, Flavio ; Isiordia-Espinoza, Mario A ; Luque Contreras, Diana ; Zapata Morales, Juan R ; Gonzalez-Rivera, Maria L</creatorcontrib><description>Abstract Fluoroquinolone agents are used widely for the treatment of infectious diseases which are a common cause of deaths around the world. The level of oxidative stress in patients taking fluoroquinolone antibiotics has not been considered a factor to reduce the clinical efficacy of this kind of drugs. Patients with diabetes and/or cardiovascular diseases present abnormal levels of oxidative stress in the blood stream. In this regards, our hypothesis supposes that patients with diabetes and/or cardiovascular disease suffering a bacterial disease could experience a therapeutic failure and bacterial resistance when treated with fluoroquinolones. The crucial mechanism could be an inefficient blood distribution of the drug via red blood cell dysfunction induced by oxidative stress that might reduce the pharmacokinetic-pharmacodinamic ratios. In this way, we review the scientific information to support our hypothesis alongside possible implications. Additionally, this work exhibits the urgent need of studies considering these conditions for quinolone agents.</description><identifier>ISSN: 0306-9877</identifier><identifier>EISSN: 1532-2777</identifier><identifier>DOI: 10.1016/j.mehy.2017.04.004</identifier><identifier>PMID: 28571804</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Adenosine Triphosphate - metabolism ; Anti-Bacterial Agents - therapeutic use ; Antioxidants - metabolism ; Area Under Curve ; Bacterial Infections - complications ; Bacterial Infections - drug therapy ; Cardiovascular Diseases - complications ; Cardiovascular Diseases - drug therapy ; Diabetes Complications - drug therapy ; Diabetes Mellitus - drug therapy ; Drug Resistance, Bacterial ; Fluoroquinolones - therapeutic use ; Humans ; Internal Medicine ; Models, Theoretical ; Oxidative Stress ; Signal Transduction</subject><ispartof>Medical hypotheses, 2017-06, Vol.103, p.32-34</ispartof><rights>Elsevier Ltd</rights><rights>2017 Elsevier Ltd</rights><rights>Copyright © 2017 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-c6a2cbd9293ad6ad8a826ae4e12a51b97689023afd8b3402e2ff3c770d735ec83</citedby><cites>FETCH-LOGICAL-c411t-c6a2cbd9293ad6ad8a826ae4e12a51b97689023afd8b3402e2ff3c770d735ec83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28571804$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aragon-Martinez, Othoniel H</creatorcontrib><creatorcontrib>Martinez-Morales, Flavio</creatorcontrib><creatorcontrib>Isiordia-Espinoza, Mario A</creatorcontrib><creatorcontrib>Luque Contreras, Diana</creatorcontrib><creatorcontrib>Zapata Morales, Juan R</creatorcontrib><creatorcontrib>Gonzalez-Rivera, Maria L</creatorcontrib><title>Bacterial resistance and failure of clinical cure could be produced by oxidative stress in patients with diabetes or cardiovascular diseases during fluoroquinolone therapy</title><title>Medical hypotheses</title><addtitle>Med Hypotheses</addtitle><description>Abstract Fluoroquinolone agents are used widely for the treatment of infectious diseases which are a common cause of deaths around the world. The level of oxidative stress in patients taking fluoroquinolone antibiotics has not been considered a factor to reduce the clinical efficacy of this kind of drugs. Patients with diabetes and/or cardiovascular diseases present abnormal levels of oxidative stress in the blood stream. In this regards, our hypothesis supposes that patients with diabetes and/or cardiovascular disease suffering a bacterial disease could experience a therapeutic failure and bacterial resistance when treated with fluoroquinolones. The crucial mechanism could be an inefficient blood distribution of the drug via red blood cell dysfunction induced by oxidative stress that might reduce the pharmacokinetic-pharmacodinamic ratios. In this way, we review the scientific information to support our hypothesis alongside possible implications. Additionally, this work exhibits the urgent need of studies considering these conditions for quinolone agents.</description><subject>Adenosine Triphosphate - metabolism</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antioxidants - metabolism</subject><subject>Area Under Curve</subject><subject>Bacterial Infections - complications</subject><subject>Bacterial Infections - drug therapy</subject><subject>Cardiovascular Diseases - complications</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Diabetes Complications - drug therapy</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Drug Resistance, Bacterial</subject><subject>Fluoroquinolones - therapeutic use</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Models, Theoretical</subject><subject>Oxidative Stress</subject><subject>Signal Transduction</subject><issn>0306-9877</issn><issn>1532-2777</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9UsuO1DAQjBCIHRZ-gAPykcuEtp3EiYSQYMVLWokDIHGzOnaH8ZCJg-0MzDfxkzjMLgcOnLrVXVWyq7ooHnMoOfDm2b480O5UCuCqhKoEqO4UG15LsRVKqbvFBiQ0265V6qJ4EOMeALpKtveLC9HWirdQbYpfr9AkCg5HFii6mHAyxHCybEA3LoGYH5gZ3eRMhph1YPwyWtYTm4O3i6Hcn5j_6SwmdyQWUxaKzE1szgOaUmQ_XNox67CnRJH5wAwG6_wRo1lGDHkVCWNe2SW46SsbxsUH_31xkx_9RCztKOB8eljcG3CM9OimXhaf37z-dPVue_3h7furl9dbU3GetqZBYXrbiU6ibdC22IoGqSIusOZ9p5q2AyFxsG0vKxAkhkEapcAqWZNp5WXx9Kw7r4-gmPTBRUPjiBP5JWreQa1kU0OVoeIMNcHHGGjQc3AHDCfNQa8h6b1eQ9JrSBoqDX9IT270l_5A9i_lNpUMeH4GUP7l0VHQ0WQns9UukEnaevd__Rf_0G8D_EYninu_hCn7p7mOQoP-uJ7JeiW8kVlSfJG_AfTSvW4</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Aragon-Martinez, Othoniel H</creator><creator>Martinez-Morales, Flavio</creator><creator>Isiordia-Espinoza, Mario A</creator><creator>Luque Contreras, Diana</creator><creator>Zapata Morales, Juan R</creator><creator>Gonzalez-Rivera, Maria L</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170601</creationdate><title>Bacterial resistance and failure of clinical cure could be produced by oxidative stress in patients with diabetes or cardiovascular diseases during fluoroquinolone therapy</title><author>Aragon-Martinez, Othoniel H ; Martinez-Morales, Flavio ; Isiordia-Espinoza, Mario A ; Luque Contreras, Diana ; Zapata Morales, Juan R ; Gonzalez-Rivera, Maria L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-c6a2cbd9293ad6ad8a826ae4e12a51b97689023afd8b3402e2ff3c770d735ec83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adenosine Triphosphate - metabolism</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antioxidants - metabolism</topic><topic>Area Under Curve</topic><topic>Bacterial Infections - complications</topic><topic>Bacterial Infections - drug therapy</topic><topic>Cardiovascular Diseases - complications</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Diabetes Complications - drug therapy</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Drug Resistance, Bacterial</topic><topic>Fluoroquinolones - therapeutic use</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Models, Theoretical</topic><topic>Oxidative Stress</topic><topic>Signal Transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aragon-Martinez, Othoniel H</creatorcontrib><creatorcontrib>Martinez-Morales, Flavio</creatorcontrib><creatorcontrib>Isiordia-Espinoza, Mario A</creatorcontrib><creatorcontrib>Luque Contreras, Diana</creatorcontrib><creatorcontrib>Zapata Morales, Juan R</creatorcontrib><creatorcontrib>Gonzalez-Rivera, Maria L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Medical hypotheses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aragon-Martinez, Othoniel H</au><au>Martinez-Morales, Flavio</au><au>Isiordia-Espinoza, Mario A</au><au>Luque Contreras, Diana</au><au>Zapata Morales, Juan R</au><au>Gonzalez-Rivera, Maria L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bacterial resistance and failure of clinical cure could be produced by oxidative stress in patients with diabetes or cardiovascular diseases during fluoroquinolone therapy</atitle><jtitle>Medical hypotheses</jtitle><addtitle>Med Hypotheses</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>103</volume><spage>32</spage><epage>34</epage><pages>32-34</pages><issn>0306-9877</issn><eissn>1532-2777</eissn><abstract>Abstract Fluoroquinolone agents are used widely for the treatment of infectious diseases which are a common cause of deaths around the world. The level of oxidative stress in patients taking fluoroquinolone antibiotics has not been considered a factor to reduce the clinical efficacy of this kind of drugs. Patients with diabetes and/or cardiovascular diseases present abnormal levels of oxidative stress in the blood stream. In this regards, our hypothesis supposes that patients with diabetes and/or cardiovascular disease suffering a bacterial disease could experience a therapeutic failure and bacterial resistance when treated with fluoroquinolones. The crucial mechanism could be an inefficient blood distribution of the drug via red blood cell dysfunction induced by oxidative stress that might reduce the pharmacokinetic-pharmacodinamic ratios. In this way, we review the scientific information to support our hypothesis alongside possible implications. Additionally, this work exhibits the urgent need of studies considering these conditions for quinolone agents.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>28571804</pmid><doi>10.1016/j.mehy.2017.04.004</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0306-9877
ispartof Medical hypotheses, 2017-06, Vol.103, p.32-34
issn 0306-9877
1532-2777
language eng
recordid cdi_proquest_miscellaneous_1905736504
source ScienceDirect Freedom Collection
subjects Adenosine Triphosphate - metabolism
Anti-Bacterial Agents - therapeutic use
Antioxidants - metabolism
Area Under Curve
Bacterial Infections - complications
Bacterial Infections - drug therapy
Cardiovascular Diseases - complications
Cardiovascular Diseases - drug therapy
Diabetes Complications - drug therapy
Diabetes Mellitus - drug therapy
Drug Resistance, Bacterial
Fluoroquinolones - therapeutic use
Humans
Internal Medicine
Models, Theoretical
Oxidative Stress
Signal Transduction
title Bacterial resistance and failure of clinical cure could be produced by oxidative stress in patients with diabetes or cardiovascular diseases during fluoroquinolone therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T12%3A21%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bacterial%20resistance%20and%20failure%20of%20clinical%20cure%20could%20be%20produced%20by%20oxidative%20stress%20in%20patients%20with%20diabetes%20or%20cardiovascular%20diseases%20during%20fluoroquinolone%20therapy&rft.jtitle=Medical%20hypotheses&rft.au=Aragon-Martinez,%20Othoniel%20H&rft.date=2017-06-01&rft.volume=103&rft.spage=32&rft.epage=34&rft.pages=32-34&rft.issn=0306-9877&rft.eissn=1532-2777&rft_id=info:doi/10.1016/j.mehy.2017.04.004&rft_dat=%3Cproquest_cross%3E1905736504%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c411t-c6a2cbd9293ad6ad8a826ae4e12a51b97689023afd8b3402e2ff3c770d735ec83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1905736504&rft_id=info:pmid/28571804&rfr_iscdi=true